Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line

Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line

Background/Aims Hepatocellular carcinoma (HCC) is the most common liver cancer with high mortality rate in patients suffering from liver diseases. The drug of choice used in advanced-stage of HCC is sorafenib. However, adaptive resistance has been observed in HCC patients undergoing long-term sorafe...

Full description

Bibliographic Details
Main Authors: Ankita Makol, Harpreet Kaur, Sakshi Sharma, Shruthi Kanthaje, Ramanpreet Kaur, Anuradha Chakraborti
Format: Article
Language:English
Published: Korean Association for the Study of the Liver 2020-01-01
Series:Clinical and Molecular Hepatology
Subjects:
carcinoma, hepatocellular
sorafenib resistance
vimentin
withaferin a
Online Access:http://e-cmh.org/upload/pdf/cmh-2019-0031.pdf

Internet

http://e-cmh.org/upload/pdf/cmh-2019-0031.pdf

Similar Items